# Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors

> **NCT00515216** · PHASE2 · COMPLETED · sponsor: **Vanderbilt University** · enrollment: 26 (actual)

## Conditions studied

- Stomach Neoplasms
- Esophageal Neoplasms

## Interventions

- **DRUG:** 5-fluorouracil
- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin

## Key facts

- **NCT ID:** NCT00515216
- **Lead sponsor:** Vanderbilt University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2011-08
- **Final completion:** 2013-11
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2016-01-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00515216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00515216, "Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00515216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*